Pain Medicine, Interventional Pain Medicine · Baton Rouge, LA
NPI
1326092610
Since 2006
Specialty
Pain Medicine, Interventional Pain Medicine
Code 208VP0014X
Group practices
1
Medicare group memberships
Hospitals
0
Hospital affiliations
9118 Bluebonnet Centre Blvd
Baton Rouge, LA, 70809
Phone (225) 368-2300
Groups this clinician bills Medicare through
Medicare paid, 2024
$495K
8,130 services
Medicare patients, 2024
396
Average age 66
Drug cost, 2024
$1.3M
41,120 prescriptions
Company payments, 2025
$535
From 7 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Alpesh D Patel was code 99214 (office e&m - established), 3,312 times for 389 patients. In total Alpesh D Patel billed 8,130 services in 31 codes, and Medicare paid $495K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2014-12-10.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 3,312 | 389 | $90.92 | $301K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 2,420 | 128 | $0.09 | $213 |
| 80307 Drug Tests | Office | 1,654 | 369 | $59.83 | $99K |
| 64483 Nerve Block Injection - Back | Office | 141 | 85 | $195.30 | $28K |
| 64484 Nerve Block Injection - Back | Office | 124 | 74 | $86.55 | $11K |
| 99406 Behavioral Health Services | Office | 81 | 57 | $14.77 | $1,196 |
| 64636 Destruction by Neurolytic Agent - Back | Office | 65 | 24 | $177.18 | $12K |
| 77002 Imaging - Miscellaneous | Office | 65 | 40 | $84.86 | $5,516 |
| 20610 Joint Injection | Office | 56 | 36 | $49.29 | $2,760 |
| 64635 Destruction by Neurolytic Agent - Back | Office | 40 | 24 | $320.55 | $13K |
| 99204 Office E&M - New | Office | 33 | 33 | $110.01 | $3,630 |
| 62321 Nerve Block Injection - Back | Office | 26 | 21 | $195.09 | $5,072 |
| 64494 Nerve Block Injection - Back | Office | 19 | 12 | $104.99 | $1,995 |
| 64493 Nerve Block Injection - Back | Office | 19 | 12 | $206.60 | $3,925 |
By year: 2022 $824K for 13,755 services; 2023 $565K for 9,476 services; 2024 $495K for 8,130 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 80307 Drug Tests | 1,654 | 369 | $59.83 | $99K |
Medicare prescription drug claims, 2024
In 2024, the drug Alpesh D Patel prescribed most often to Medicare patients was Hydrocodone-Acetaminophen (Hydrocodone/Acetaminophen), with 12,192 prescriptions and refills. In total Alpesh D Patel wrote 41,120 Medicare prescriptions that cost $1.3M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 12,192 | 12,192 | 1,320 | $302K |
| Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen | 7,577 | 7,578 | 827 | $223K |
| Gabapentin Generic | 3,425 | 5,100 | 800 | $54K |
| Oxycodone Hcl Generic | 2,086 | 2,086 | 234 | $36K |
| Cyclobenzaprine Hcl Generic | 2,040 | 3,049 | 525 | $26K |
| Tizanidine Hcl Generic | 1,789 | 2,656 | 377 | $24K |
| Tramadol Hcl Generic | 1,228 | 1,228 | 228 | $9,711 |
| Meloxicam Generic | 1,151 | 1,713 | 314 | $4,005 |
| Morphine Sulfate Er Morphine Sulfate | 1,000 | 1,002 | 103 | $22K |
| Zolpidem Tartrate Generic | 965 | 968 | 118 | $4,857 |
| Nabumetone Generic | 862 | 964 | 260 | $9,676 |
| Pregabalin Generic | 833 | 853 | 146 | $15K |
| Baclofen Generic | 540 | 857 | 132 | $6,999 |
| Methocarbamol Generic | 508 | 687 | 160 | $7,922 |
| Morphine Sulfate Generic | 447 | 447 | 53 | $13K |
Brand drugs: 960 claims; generic drugs: 40,160 claims; opioid claims: 25,101.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Alpesh D Patel $535 ($535 in general payments such as food, travel and fees) from 7 companies. The largest payer was Valinor Pharma, LLC with $230.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.